• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Severe Neurological Involvement in an Adult with Shiga Toxin-Producing < i > Escherichia coli < /i > -Hemolytic Uremic Syndrome Treated with Eculizumab
A 68-year-old man with a medical history of hypertension was admitted to the emergency department for diffuse abdominal pain preceded by bloody diarrhea. Upon admission, neurological examination was normal, but he suddenly developed a left-sided hemiparesis. After a normal brain computed tomography, intravenous thrombolysis was administered for a suspicion of ischemic stroke. In the first laboratory investigations, hemoglobin was 16.9 g/dL, platelets 121 × 109/L (150 –450), and serum creatinine 1.17 mg/dL. By the second hospital day, the platelet level dropped to 79 × 109/L, with haptoglobin at 0.12 g/L, 3% schistocyte...
Source: Case Reports in Nephrology and Dialysis - January 27, 2023 Category: Urology & Nephrology Source Type: research

Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS)
AbstractHemolytic uremic syndrome is commonly caused by Shiga toxin-producingEscherichia coli (STEC). Up to 15% of individuals with STEC-associated hemorrhagic diarrhea develop hemolytic uremic syndrome (STEC HUS). Hemolytic uremic syndrome (HUS) is a disorder comprising of thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury. The kidney is the most commonly affected organ and approximately half of the affected patients require dialysis. Other organ systems can also be affected including the central nervous system and the gastrointestinal, cardiac, and musculoskeletal systems. Neurological complicat...
Source: Pediatric Nephrology - October 29, 2019 Category: Urology & Nephrology Source Type: research

Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Etiology and Outcomes of Thrombotic Microangiopathies.
CONCLUSIONS: Secondary thrombotic microangiopathies represent the majority of thrombotic microangiopathies. Multiple thrombotic microangiopathies causes are present in one half of secondary thrombotic microangiopathies. The risks of dialysis, neurologic and cardiac complications, and death vary by the cause of thrombotic microangiopathies. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_03_12_CJASNPodcast_19_04_.mp3. PMID: 30862697 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - March 11, 2019 Category: Urology & Nephrology Authors: Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, Mérieau E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Buchler M, Vigneau C, Fakhouri F, Halimi JM Tags: Clin J Am Soc Nephrol Source Type: research

Subarachnoid Hemorrhage as the Initial Neurologic Manifestation in Thrombotic Thrombocytopenic Purpura (P6.014)
Conclusion: Upon review of the literature, ischemic infarction and intracerebral hemorrhage are uncommon complications of TTP. Our case demonstrates a unique case of subarachnoid hemorrhage as the initial neurological manifestation of TTP.Disclosure: Dr. Wei has nothing to disclose. Dr. Ramesh has nothing to disclose. Dr. Farmakidis has nothing to disclose. Dr. Nalleballe has nothing to disclose. Dr. JADEJA has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Wei, J., Ramesh, A., Farmakidis, C., Nalleballe, K., Jadeja, N. Tags: Cerebrovascular Disease and Interventional Neurology II ePosters Source Type: research